Key facts
- It has raised $7.0M.
- Notable investors include Arches Capital, BOP Impact Ventures, Colby Souders, Eurostars, Nextgen Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Enpicom
- ·The full record, as it builds
Funding rounds
No funding rounds for Enpicom are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enpicom
Developer of bioinformatics software designed to help decode the immune system and improve human health. The company's technology-agnostic, code-free software removes the complexity of managing and analyzing immune repertoire sequencing data and provides an antibody discovery process, enabling scientists to focus on their research, discoveries, and development.
- Sector
- Healthcare
- HQ
- 's-Hertogenbosch, Netherlands
- Founded
- 2015
- Employees
- 15
- Website
- enpicom.com/
- Ownership
- Privately Held (backing)
Enpicom doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enpicom shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enpicom in its N-PORT filings yet. We sweep new filings monthly.